Clinical Trial Update: A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients [Phase 3]

View source ↗

Summary

Phase III trial evaluating TG-2349 in combination with DAG181 and RBV for chronic hepatitis C virus genotype 1 patients in non-cirrhotic status has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• DAG181
• RBV (ribavirin)
• TG-2349

Snippet

Sponsor: Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | Conditions: Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic | Phase 3 | Status: COMPLETED